Virax Biolabs Group Ltd Dossier - Source-backed chat

Virax Biolabs Group Ltd

VRAXNASDAQ

SectorHealth Care

IndustryBiotechnology

Beta (adjusted)1.18

Intrinsic Value

Insufficient data for a value estimateNot enough reliable inputs to publish a fair value for this company yet.

Market Price $2.18Price as of 30 Sep 2026

Data confidenceNot applicable

Market Cap $1.7M

Enterprise Value −$2.2M

Shares Outstanding 797K diluted

Next Earnings Date31 Dec 2026

All prices and values are periodic snapshots, not live quotes. Source dates are shown for reference.

Thesis

Street consensus, scenarios, merits, risks, and invalidation triggers

AI-assisted

Thesis Summary

Virax Biolabs Group Ltd is a micro-cap biotechnology company transitioning from planning to clinical execution. The company is developing ViraxImmune™, a novel T-cell-based immunology profiling platform targeting post-acute infection syndromes (PAIS) such as Long COVID, ME/CFS, and post-treatment Lyme disease. With positive early pilot data (88% specificity and 92% PPV) and a debt-free balance sheet holding approximately $6.4 million in cash (exceeding its current market capitalization of ~$2.6 million as of April 2026), the stock trades at a negative enterprise value. This cash-rich valuation gap provides a significant margin of safety, while upcoming clinical validation readouts and a planned U.S. Laboratory Developed Test (LDT) market entry serve as major near-term catalysts.

This section is the 12-month view: analyst targets and the probability-weighted scenarios built from them. The intrinsic value at the top of this page answers a different question: what the business is worth today.

Street view · analyst 12-month targets1 analysts · as of 18 Aug 2026

Low · most bearish analyst$25.00

Mean target$25.00

High · most bullish analyst$25.00

Our research · scenarios, merits, risks, and invalidation triggersResearch as of 20 Jun 2026

Scenarios · 12-month scenario targetsAnchored at research date

Bear CaseDownside scenario

$0.1020%

The larger clinical validation study fails to replicate the high specificity and PPV of the pilot dataset, delaying or invalidating the U.S. LDT market-entry strategy. Persistent operating losses exhaust the company's cash reserves faster than anticipated, forcing highly dilutive equity raises. The reverse split fails to sustain the stock price above Nasdaq's minimum requirements, leading to delisting pressures.

Base CaseCentral scenario

$1.0050%

Virax successfully initiates its larger clinical validation analysis in Q4 2026, with results in Q1 2027 matching the pilot dataset. The company executes its approved reverse share split to maintain compliance with Nasdaq's minimum bid price requirement, stabilizing the capital structure. U.S. clinical validation planning with Emory University progresses steadily, and the company maintains its debt-free status while gradually burning its cash reserves to fund operations.

Bull CaseUpside scenario

$1.0030%

The larger clinical validation study of 300 participants confirms or exceeds the pilot performance metrics (88% specificity, 92% PPV). Virax successfully launches ViraxImmune™ as a Laboratory Developed Test (LDT) in the U.S. through CLIA-certified lab partners, capturing a meaningful share of the estimated 21 million U.S. adults living with Long COVID. Commercial uptake of the ImmuneSelect research-use-only (RUO) products accelerates, driving near-term revenue and leading to a significant upward re-rating of the stock toward the consensus analyst price target.

Scenarios are anchored to street consensus at the research date, with our probabilities and rationale.

Key Investment Merits

Strong balance sheet with approximately $6.4 million in cash and no long-term debt as of March 31, 2026, representing a negative enterprise value relative to its micro-cap valuation.
Encouraging early pilot performance data for ViraxImmune™ showing 88% specificity and 92% positive predictive value in separating PAIS patients from healthy controls.
Clear, lower-barrier regulatory pathway via the U.S. Laboratory Developed Test (LDT) route prior to pursuing broader in vitro diagnostic (IVD) approvals.
Targeting a massive, under-served global market with up to 21 million U.S. adults estimated to be living with Long COVID and related post-acute infection syndromes.

Key Investment Risks

Extremely low trailing revenue ($2,986 TTM) and persistent operating losses ($5.64 million TTM net loss) as the company remains in a pre-commercial R&D phase.
High clinical and regulatory risk, with the ultimate commercial viability of ViraxImmune™ dependent on the outcomes of larger validation studies and FDA/CLIA requirements.
Potential equity dilution from future capital raises or the utilization of the 2026 Equity Incentive Plan.
Nasdaq listing compliance risk, requiring a reverse share split to maintain the minimum bid price requirement.

Thesis Invalidation Triggers

Failure of the larger 300-participant clinical validation study to demonstrate statistically significant separation between PAIS patients and healthy controls.
Inability to secure partnerships with CLIA-certified laboratories for the U.S. launch of the ViraxImmune™ LDT.
Rapid cash burn exceeding $1.5 million per quarter, leading to premature and highly dilutive equity financing.
Delisting from the Nasdaq Capital Market due to failure to maintain minimum bid price or shareholder equity requirements.

All scenarios are estimates and subject to change. Past performance is not indicative of future results.

Quality Pillars Members

This section is available to registered members. Create a free account or sign in to unlock the full breakdown.

Explore this dossier

ValuationIntrinsic value, the six-method breakdown, peer medians, and your assumptions sandbox.Financial SnapshotRevenue, profitability, returns, balance sheet, dividends, and the filing-level detail.Qualitative AnalysisBusiness overview, strategic initiatives, and mergers, acquisitions & partnerships.Outlook & Key DatesForward estimates, reporting calendar, and the monitoring framework.